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Neurobiology of Disease
Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to
Normalize Hippocampal Synaptic Function and Plasticity in
a Rat Model of Traumatic Brain Injury
Jennifer L. Furman,1* Pradoldej Sompol,2* X Susan D. Kraner,2 Melanie M. Pleiss,1,2 Esther J. Putman,2
X Jacob Dunkerson,2 Hafiz Mohmmad Abdul,2 Kelly N. Roberts,2 Stephen W. Scheff,2,3 and Christopher M. Norris1,2
1Department of Pharmacology and Nutritional Sciences, 2Sanders-Brown Center on Aging, and 3Department of Anatomy and Neurobiology, University of
Kentucky College of Medicine, Lexington, Kentucky 40536
Increasing evidence suggests that the calcineurin (CN)-dependent transcription factor NFAT (Nuclear Factor of Activated T cells) medi-
ates deleterious effects of astrocytes in progressive neurodegenerative conditions. However, the impact of astrocytic CN/NFAT signaling
on neural function/recovery after acute injury has not been investigated extensively. Using a controlled cortical impact (CCI) procedure
in rats, we show that traumatic brain injury is associated with an increase in the activities of NFATs 1 and 4 in the hippocampus at 7 d after
injury. NFAT4, but not NFAT1, exhibited extensive labeling in astrocytes and was found throughout the axon/dendrite layers of CA1 and
the dentate gyrus. Blockade of the astrocytic CN/NFAT pathway in rats using adeno-associated virus (AAV) vectors expressing the
astrocyte-specific promoter Gfa2 and the NFAT-inhibitory peptide VIVIT prevented the injury-related loss of basal CA1 synaptic strength
and key synaptic proteins and reduced the susceptibility to induction of long-term depression. In conjunction with these seemingly
beneficial effects, VIVIT treatment elicited a marked increase in the expression of the prosynaptogenic factor SPARCL1 (hevin), espe-
cially in hippocampal tissue ipsilateral to the CCI injury. However, in contrast to previous work on Alzheimer’s mouse models, AAV-
Gfa2-VIVIT had no effects on the levels of GFAP and Iba1, suggesting that synaptic benefits of VIVIT were not attributable to a reduction
in glial activation per se. Together, the results implicate the astrocytic CN/NFAT4 pathway as a key mechanism for disrupting synaptic
remodeling and homeostasis in the hippocampus after acute injury.
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Introduction
Astrocytes exhibit striking morphological changes with CNS in-
jury and disease, which are collectively referred to as “astrocyte
activation” (Pekny and Nilsson, 2005; Parpura et al., 2012; An-
derson et al., 2014). Hypertrophy of astrocyte somata and pro-
cesses, along with a corresponding increase in the expression of
the glial fibrillary acidic protein (GFAP), are the most robust and
recognizable biomarkers of activated astrocytes, yet the func-
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Significance Statement
Similar to microglia, astrocytes become strongly “activated” with neural damage and exhibit numerous morphologic/biochemical
changes, including an increase in the expression/activity of the protein phosphatase calcineurin. Using adeno-associated virus
(AAV) to inhibit the calcineurin-dependent activation of the transcription factor NFAT (Nuclear Factor of Activated T cells)
selectively, we have shown that activated astrocytes contribute to neural dysfunction in animal models characterized by progres-
sive/chronic neuropathology. Here, we show that the suppression of astrocytic calcineurin/NFATs helps to protect synaptic
function and plasticity in an animal model in which pathology arises from a single traumatic brain injury. The findings suggest
that at least some astrocyte functions impair recovery after trauma and may provide druggable targets for treating victims of acute
nervous system injury.
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tional phenotype of these cells appears highly complex. In intact
animal models, targeted approaches for inhibiting GFAP expres-
sion or for modulating the activity of major astrocytic signaling
pathways have demonstrated both protective and deleterious
roles of activated astrocytes in neural function depending on the
nature of the injury (e.g., chronic neurodegeneration vs acute
trauma) and the proximity of astrocytes to the site of injury/
pathology, among many other factors (Sofroniew, 2009; Pekny
and Pekna, 2014; Pekny et al., 2014; Burda et al., 2015).
Several key morphologic and biochemical features of astro-
cyte activation have been linked to the expression and/or
hyperactivation of the Ca 2/calmodulin-dependent protein
phosphatase calcineurin (CN) (Norris et al., 2005; Fernandez et
al., 2007; Canellada et al., 2008; Furman et al., 2012; Furman and
Norris, 2014). Although weakly expressed in astrocytes in healthy
adult nervous tissue, CN can appear at high levels in activated
astrocytes associated with aging (Norris et al., 2005), acute injury
(Hashimoto et al., 1998), and progressive amyloid pathology
(Norris et al., 2005; Celsi et al., 2007; Abdul et al., 2009). In
peripheral tissues, including lymphoid tissue, heart, vascular
smooth muscle cells, and skeletal muscle, CN is known to
strongly regulate the morphological and functional phenotypes
of cells through the activation of NFAT (Nuclear Factor of Acti-
vated T cells) transcription factors (Crabtree and Olson, 2002;
Horsley and Pavlath, 2002; Hogan et al., 2003; Wilkins and Molk-
entin, 2004; Hassoun et al., 2009). There are four CN-dependent
NFAT isoforms (i.e., NFATs 1– 4), all of which are expressed in
mammalian brain (Nguyen and Di Giovanni, 2008; Vihma et al.,
2008). Changes in NFAT expression/activity, especially for the
NFAT1 and 4 isoforms, have been observed in astrocytes in pro-
gressive neurodegenerative conditions such as Alzheimer’s dis-
ease (AD) (Abdul et al., 2009) and Parkinson’s disease (Caraveo
et al., 2014) and also after acute nervous system injury (Serrano-
Pérez et al., 2011; Yan et al., 2014). Blockade of CN/NFAT inter-
actions in astrocytes using adeno-associated virus (AAV) vectors
and the CN docking site mimetic peptide VIVIT suppressed glial
activation, reduced amyloid pathology, and improved synaptic
function in a mouse model of AD (Furman et al., 2012), suggest-
ing that astrocytic CN/NFAT signaling may be detrimental
to neural function in chronic neurodegenerative conditions.
Whether CN/NFAT plays a similarly deleterious role in activated
astrocytes after acute neural injury is unknown.
Here, we investigated the DNA-binding activities of all four
CN-dependent NFAT isoforms in rat hippocampus 7 d after a
unilateral cortical contusion injury (CCI). Although we found
evidence for increased expression of the NFAT1 and 4 isoforms,
specific colocalization with GFAP-positive astrocytes was only
observed for NFAT4. Intrahippocampal injection of AAV vectors
containing the astrocyte-specific promoter Gfa2 and the NFAT
inhibitory peptide VIVIT prevented the weakening of basal CA3–
CA1 synaptic strength, reduced susceptibility to long-term syn-
aptic depression (LTD), and protected against the loss of several
key synaptic proteins. However, AAV-Gfa2-VIVIT did not ap-
preciably alter astrocyte or microglial protein markers (i.e., GFAP
and Iba-1, respectively). The results suggest that astrocytic CN/
NFAT signaling can impair and/or prevent the recovery of syn-
aptic function after traumatic brain injury without reducing
astrocyte activation per se.
Materials and Methods
Animals and TBI. Adult (2-month-old) male Sprague Dawley rats
(250 –275 g; Harlan Laboratories) were housed 2/cage on a 12 h light/
dark cycle, provided access to food and water ad libitum, and used in
accordance with the Institutional Animal Care and Use Committee of the
University of Kentucky. Stereotaxic surgeries and delivery of traumatic
brain injury was performed with slight modifications of our previous
methods (Norris and Scheff, 2009; Ansari et al., 2013; Scheff et al., 2013).
Briefly, rats were anesthetized with 2% isofluorane and immobilized in a
Kopf stereotaxic frame with the incisor bar set at 5. Body temperature
for each rat was monitored and maintained at 36°C with a Space Gel
heating pad (Braintree Scientific). After a midline incision and retraction
of the skin, a 6-mm-diameter craniotomy was made lateral to midline
and approximately midway between bregma and lambda with a Michele
hand trephine and the skull disk was removed without disturbing the
dura. An electronic controlled pneumatic impact device (TBI0310; Pre-
cision System) with a hard stop Bimba cylinder was used to deliver a
moderate unilateral controlled cortical impact (CCI) injury, which com-
pressed the cortex to a depth of 2.0 mm at a velocity of 3.5 m/s. After the
injury, the craniotomy site was sealed with MASCOT adhesive (EMS)
and an 8 mm disc formed from clear polyester (0.5 mm; Midwest Prod-
ucts). In some cases, rats were subjected to craniotomy, but did not
receive a CCI, and served as sham controls. The surgical procedure was
completed in 15–20 min.
Electrophoretic mobility shift assay. As the EMSA probe, a duplex DNA
oligonucleotide labeled on its 5 ends with IRDye 700 (LI-COR) was ob-
tained from Integrated DNA Technologies. The sequence of the strands were
(5-IRDye700-ACATTGGAAAATTTTATTACACCA-3 annealed to 5-
IRDye700-TGGTGTAATAAAATTTTCCAATGT-3) and corresponded to
the NFAT binding site from the IL4 promoter, with which previous high-
quality EMSAs have been performed by others (Neal and Clipstone, 2001).
Probe specificity was assessed using an unlabeled wild-type competitor of the
same sequence or a mutant competitor containing an altered NFAT-binding
site (TGGAAAA¡ CTTTAAA). When indicated, these competitors were
included at a 100-fold molar excess in the EMSA-binding mix.
Whole cell extracts from frozen brain tissue at 7 d after CCI were made
using a kit from Active Motif following the manufacturer’s instructions
and protein assays performed using a Bradford assay. The binding reac-
tion used for these experiments contained 10 mM Tris, pH 7.5, 50 mM
NaCl, 1 mM EDTA, 1 mM DTT, 0.05% NP40, 5% glycerol, 0.5 g of poly
dIC, 5 g of BSA, 10% 10 orange loading buffer (LI-COR), 1% pro-
tease inhibitor mixture III (EMD Millipore), and 1% phosphatase inhib-
itor mixture II (EMD Millipore), indicated extract, and 10 femtomoles of
IL4 NFAT probe. To induce supershift/blockshift with NFAT antibodies,
3.3 l of the indicated NFAT antibody was added to the mixture and 3.3
l of PBS to the negative control. NFAT1 (Abcam, catalog #ab2272),
NFAT2 (Santa Cruz Biotechnology, catalog #sc-13033x), NFAT3 (Santa
Cruz Biotechnology, catalog #sc-13036x), and NFAT4 (Santa Cruz Bio-
technology, catalog #sc-8405x) were used individually. For some condi-
tions, NFAT1 and NFAT4 antibodies were used in combination, as
indicated. EMSA samples were incubated on ice for 2 h, covered with
foil to protect fluorescent probe from photobleaching, and incubated
at room temperature for 10 min before loading on gels. Electropho-
resis was performed on chilled 5% nondenaturing polyacrylamide
gels in 1⁄2 TBE running buffer in a cold room for 1 h and 50 min at
200 V, covering the apparatus with foil and keeping the lights out. The
orange dye/free NFAT probe was close to the bottom of the gel at the
end of the gel run. Images were obtained on an Odyssey scanner
(LI-COR) using the 700 channel at the highest intensity and Image
Studio 2.1 software (LI-COR) was used to quantify fluorescence of
shifted bands. Protein concentrations used in these studies were op-
timized from titration assays (data not shown) and fell within the
linear detection range of the Odyssey scanner. Control (contralateral
side of the hippocampus) and injured (ipsilateral side of the hip-
pocampus) tissue samples were run on the same gel for direct statis-
tical comparisons.
Correspondence should be addressed to Dr. Christopher M. Norris, Department of Pharmacology and Nutritional
Sciences, University of Kentucky College of Medicine, 224 Sanders-Brown Building, 800 South Limestone St., Lex-
ington, KY 40536. E-mail: cnorr2@uky.edu.
DOI:10.1523/JNEUROSCI.1930-15.2016
Copyright © 2016 the authors 0270-6474/16/361503-14$15.00/0
Furman, Sompol et al. • Astrocytic NFAT Signaling and Traumatic Brain Injury J. Neurosci., February 3, 2016 • 36(5):1502–1515 • 1503
Immunofluorescent labeling of NFAT isoforms in brain sections. On day
7 of recovery after treatment with cortical contusion injury, rats were
deeply anesthetized and perfused with 50 ml of saline followed by 100 ml
of a solution of 4% paraformaldehyde, pH 7.4. After perfusion, the brains
were removed from the skull, further fixed for an additional 4 h, and then
put in a 30% sucrose solution. Coronal brain sections (40 m) were
made and the sections stored in the sucrose solution in a 20 freezer. As
needed, sections were removed and stained as free-floating sections in
12-well tissue culture plates using a bent glass pipette to transfer brain
section from well to well containing the appropriate solution. Brain sec-
tions were rinsed 2 with TBS buffer (100 mM Tris, pH 7.5, 0.85%
saline), treated with H2O2 solution (3% H2O2, 10% methanol in TBS) for
60 min, and then rinsed again with TBS buffer. Sections were pretreated
with TBS-T (TBS with 0.1% Triton X-100) and blocked with TBS-BSA
(2% BSA in TBS-T). First antibodies, the same ones used for the EMSAs
(either NFAT1, Abcam, catalog #ab2722, 1:100 dilution, or NFAT4,
Santa Cruz Biotechnology, catalog #sc-8405, 1:20 dilution) were diluted
in TBS-BSA and brain sections were incubated overnight at 4 C with
rotation on a shaker. The next morning, sections were washed 3 in
TBS-T and then blocked in TBS-BSA. The secondary antibody (to the
mouse primaries) and an Alexa Fluor 488-tyramide from a tyramide
signal amplification kit (Invitrogen, catalog #T20912) were used accord-
ing to the manufacturer’s directions. After additional washes in TBS-T,
the sections were blocked again in TBS-BSA and incubated with directly
conjugated Alexa Fluor 594-monoclonal Ab to GFAP (Cell Signaling
Technology, catalog #8152) at a 1:100 dilution overnight at 4°C. After
washes in TBS-T, the sections were mounted on gelatin-coated micro-
scope slides and coverslipped with DAPI-containing Prolong Gold Anti-
fade Mounting Medium (Invitrogen, catalog #P36931). Fluorescent
images were obtained on a confocal microscope (Nikon Eclipse Ti) and
contralateral and ipsilateral sides were taken at the same settings so that
quantitative comparisons could be made between the two sides. Images
shown are single plane projections of focused stacks of images. NFAT4
nuclear/cytosolic localization images (taken with a 100 objective) were
obtained from enhanced green fluorescent protein (EGFP)-positive cells
in the dendritic layers of CA1 and the dentate gyrus in a Z-series of 0.5
m steps. Images used for quantification were randomly acquired and
measured by personnel blind to the experimental condition. Cytosolic
and nuclear NFAT4 fluorescence intensities were quantified by Imaris
8.1.3 software.
AAV delivery. AAV2/5 vectors constructed using rep and cap genes
from AAV2 and AAV5 serotypes, respectively (Hildinger et al., 2001),
were obtained from the UPENN virus core. Vectors expressed EGFP
alone or EGFP fused to the NFAT inhibitory peptide VIVIT. Transgene
expression was under the control of the human GFAP promoter (Gfa2)
isolated and characterized by Dr. Michael Brenner’s laboratory at the
University of Alabama–Birmingham (de Leeuw et al., 2006; Lee et al.,
2008). Methods for the bilateral delivery of AAV vectors to rat hippocam-
pus were adapted, with slight modifications, from our previous work on
mice (Furman et al., 2012). Briefly, rats were placed in a stereotaxic frame
under isoflurane anesthesia as described above. After a midline incision,
holes were drilled bilaterally and needles attached to separate Hamilton
syringes containing AAV vectors (10 12 ifu/ml) were lowered into the
hippocampus and injected at a rate of 0.2 l/min (8 l total) using a
stereotaxic microinjector (Stoelting). Syringe needles were left in place
for 2 min after completion to limit reflux. Coordinates for injection
relative to bregma were 3.8 mm anteroposterior, 1.8 mm mediolat-
eral, and 2.8 mm dorsoventral. Wounds were closed and rats were
returned to their home cages for 8 weeks before receiving a unilateral
CCI injury, as described above.
Astrocyte immunodepletion and AAV specificity. At 4 weeks after AAV-
Gfa2-EGFP injection, some rats were anesthetized under CO2 and decap-
itated, with hippocampi dissected away and stored in ice-cold Ca 2/
Mg 2-free PBS solution. Hippocampal tissue then was minced finely in
a Petri dish, treated with 0.125% trypsin-EDTA, and transferred to a
conical tube (in a total volume of 2 ml) using a 1000 l pipet tip. After 15
min, samples were triturated first with a 1000 l pipet tip, then with a 200
l tip (placed over the end of a 1000 l pipet tip). The sample was then
diluted with 2 ml of PBS with 0.5% BSA (buffer) and incubated for an
additional 15 min to allow larger fragments of undigested tissue to settle
out. The supernatant was passed through a 70 m filter and the cells
centrifuged 2 at 300  g for 10 min (to remove all trypsin) and resus-
pended in buffer. After the final spin, cells were resuspended in 4 ml of
buffer. A small sample was diluted 1:10, treated with trypan blue, and
examined on a hemocytometer to determine both cell number and the
quality of the single-cell suspension. Typical yields using this method
were 1–5  10 8 cells.
For cell separation, 5  10 7 cells from each sample were pelleted at
300  g for 10 min and taken up in 100 l buffer with 150 l of mouse
GLAST antibody (Miltenyi Biotec pure GLAST Ab). “Mock” separations
(i.e., in which no GLAST antibody was added) were performed in paral-
lel. Cells were then resuspended by pipetting up and down (never vor-
texed) and incubated for 13 min at 4°C. Cells were pelleted (300  g for
10 min), washed 3 (to remove excess antibody), resuspended in 200 l
of buffer containing 40 l of preequilibrated Dynabeads (Invitrogen),
and incubated at 4°C for another 15 min. The astrocyte-enriched (AE)
fraction bound to the beads was captured to the side of the tube using a
chilled Mag-Rack (GE Healthcare) and the astrocyte-depleted (AD) frac-
tion removed. To ensure removal of all Dynabeads, the AD fraction
underwent a second round in the Mag-Rack and the suspension was
extracted. This fraction was then pelleted to concentrate the cells. The AE
fraction was washed 3 in buffer, capturing it in the Mag-Rack each time
to maximize astrocyte enrichment. After each wash, the fraction was
resuspended and placed in the Mag-Rack to maximize astrocyte enrich-
ment. At the end of the separation procedure, the AD and AE fractions,
along with mock-enriched (ME) and mock-depleted (MD) fractions
(i.e., fractions not exposed to GLAST antibody) were dissolved in 60 – 80
l of 2 sample buffer, heated at 65°C for 20 min, and then transferred
to separate lanes of a 4 –20% Criterion gradient gel (Bio-Rad) for SDS-
PAGE. The gel was then transferred to Immobilon-FL PVDF membranes
(Millipore, catalog #IPFL 00010). Western blots were performed using
primary antibodies to GFAP (rabbit; Cell Signaling Technology), EGFP
(rabbit; Abcam), and -actin (mouse; Sigma-Aldrich).
Preparation of hippocampal slices. Methods for preparing hippocampal
slices from brain-injured rats are nearly identical to our previous work
(Norris and Scheff, 2009). Briefly, at 7 d after CCI, rats were killed under
CO2 anesthesia and decapitated. Brains were rapidly removed and placed
in ice-cold, oxygenated (95% O2, 5% CO2) artificial CSF (ACSF) con-
taining the following (in mM): 124 NaCl, 2 KCl, 1.25 KH2PO4, 2 MgSO4,
0.5 CaCl2, 26 NaHCO3, and 10 dextrose, pH 7.4. Hippocampi were
bilaterally dissected and sectioned coronally into 400 – 450 m slices
using a McIlwain Tissue Chopper (Stoelting). Slices were then trans-
ferred to a custom interface holding chamber (Mathis et al., 2011) and
incubated with warmed (32°C) oxygenated ACSF containing 2 mM CaCl
until electrophysiological recordings (usually 1.5–5 h).
Electrophysiological analysis of CA1 synaptic function. Slices were sub-
merged in oxygenated ACSF (32°C) and perfused at a rate of 1–2 ml/min
in an RC22 chamber (Warner Instrument). Schaffer collaterals were ac-
tivated with a bipolar platinum/iridium electrode located in stratum
radiatum near the CA3–CA1 border. Stimulus intensity was controlled
by a constant current stimulus isolation unit (World Precision Instru-
ments) and stimulus timing was controlled by Clampex 9.2 software
(Molecular Devices). Field potentials were recorded in CA1 stratum ra-
diatum using a glass micropipette (1– 6 M) and filled with ACSF con-
taining an Ag/AgCl wire. Physiologic activity was amplified 100,
Bessel-filtered at 1 kHz, and digitized at 10 kHz using a Multiclamp 700B
amplifier and a Digidata 1320 digitizer (Molecular Devices).
To assess basal synaptic strength, 100 s stimulus pulses were given at
nine intensity levels (range 30 –500 A) at a rate of 0.1 Hz. Five field
potentials at each level were averaged, and measurements of fiber volley
(FV) amplitude (in millivolts) and EPSP slope (in millivolts/millisecond)
were performed offline using Clampfit software (Molecular Devices). FV
amplitudes were plotted against stimulation intensity to estimate the
relative level of presynaptic excitability and EPSP slope measures were
plotted against their corresponding FV amplitudes to estimate the rela-
tive strength of CA3–CA1 synapses. Synaptic strength curves for each
hemisphere were fit (SigmaPlot 12; Systat Software) with a sigmoidal
equation of the form:
1504 • J. Neurosci., February 3, 2016 • 36(5):1502–1515 Furman, Sompol et al. • Astrocytic NFAT Signaling and Traumatic Brain Injury
a
 1  exp x  x0b 
Where a equals the maximal amplitude of the curve, b equals the curve
slope, x equals the FV amplitude, and x0 equals the FV amplitude re-
quired for half-maximal EPSP amplitude. Synaptic strength was also
estimated by averaging the EPSP/FV ratio across the top three stimulus
levels of the input output curve.
Methods for inducing and measuring LTD are similar to those used
in our previous work (Norris et al., 1996; Sama et al., 2012; Norris et
al., 2016). After input/output curves, single-stimulus pulses were de-
livered at a rate of 0.033 Hz to establish a baseline. Although the 1⁄2
maximal stimulus intensity from the input/output curve is often used
for setting the baseline and LTD stimulation levels, we instead used
the stimulus intensity necessary to elicit an 1 mV EPSP. This pro-
cedure was implemented to minimize possible hemispheric differ-
ences in the level of postsynaptic depolarization achieved during LTD
induction (see discussion in Norris and Scheff, 2009; Mathis et al.,
2011). It is well established that the induction of both LTD and long-
term potentiation (LTP) are strongly dependent on postsynaptic de-
polarization levels (Malinow and Miller, 1986; Wigstrom and
Gustafsson, 1986; Mulkey and Malenka, 1992). We have found that,
relative to the contralateral hemisphere, slices from the ipsilateral
hippocampus typically show reduced EPSP amplitudes (less depolar-
ization) in response to the same level of presynaptic stimulation at 7 d
aftr CCI (Norris and Scheff, 2009). Using the 1⁄2 maximal stimulus
intensity in the CCI model would therefore necessarily lead to the
elicitation of smaller EPSP amplitudes during LTD stimulation for
ipsilateral relative to contralateral slices, which may in turn negatively
affect the extent to which postsynaptic plasticity mechanisms are
engaged.
After a stable baseline period of no less than 20 min, slices received a 15
min train of 1 Hz stimulation at baseline stimulation intensity, followed
by another 60 min baseline period (stimulation rate  0.033 Hz). Within
each hemisphere, EPSP measures from the last 10 min of the post-1 Hz
stimulation baseline were averaged across slices and expressed as a per-
centage of the pre-1 Hz stimulation baseline level. Therefore, for all
electrophysiologic biomarkers, n is equal to the number of rats used
rather than the number of slices.
Western blot. On day 7 of recovery from CCI injury, hippocampi
(contralateral control and ipsilateral injured) were harvested, put into
Microfuge tubes, and snap frozen in liquid N2. Samples were stored at
80°C until needed. Samples were homogenized in PBS with a panel of
protease and phosphatase inhibitors as described previously (Ansari et
al., 2013). Lowry protein assays were performed to normalize protein
levels and 25–75 g of protein was used per gel well (depending on the
antibody used for Western analysis). Proteins were resolved on 4 –20%
Criterion gradient gels (Bio-Rad) and transferred to Immobilon-FL
PVDF membranes (Millipore, catalog #IPFL 00010). After transfer,
membranes were blocked in 50% Odyssey protein blocking reagent in
PBS and then incubated in primary antibodies in 50% Odyssey protein
blocking reagent (LI-COR) in PBS with 0.2% Tween overnight at 4°C on
a shaking platform. Westerns were performed with the following primary
antibodies: GFAP (Cell Signaling Technology, catalog #3670S), Iba1
(Wako, catalog #019-19741), PSD-95 (Cell Signaling Technology, cata-
log #3450S), synapsin-1 (Cell Signaling Technology, catalog #6710S),
GluR1 (Millipore, catalog #AB1504), NR2A (Millipore 07-632), NR2B
(Millipore, catalog #05-920), CNA (Millipore, catalog #07-1492),
GAPDH (Abcam, catalog #ab9484), hevin (R&D Systems, catalog
#MAB2836), and SPARC (R&D Systems, catalog #MAB942). Mem-
branes were then washed in PBS/0.1% Tween, incubated in LI-COR
800-conjugated anti-mouse and 680-conjugated anti-rabbit secondary
antibodies, washed, and imaged on an Odyssey Sa Imager System
(LI-COR) on both the green (800) and red (680) channels. Quantifica-
tion of bands was performed using Image Studio 2.1 software (LI-COR).
Expression was normalized to loading control GAPDH for each sample.
Statistical analyses. Unless otherwise noted, outcome measures were
assessed in both the contralateral (uninjured) and ipsilateral (injured)
hemispheres and compared across treatment groups using repeated-
measures ANOVA. When appropriate, Fisher’s protected least signifi-
cant difference test was used for post hoc analyses. Significance for all
statistical comparisons was set at p  0.05.
Results
Upregulation of NFAT expression is isoform and
cell-type specific
The role of CN/NFAT signaling in TBI was assessed using a uni-
lateral CCI model, which results in a substantial loss of CA3
neurons (Baldwin et al., 1997) and CA3–CA1 synaptic contacts in
stratum radiatum of the ipsilateral hemisphere, followed by the
partial reinnervation of CA1 during the first few weeks after in-
jury (Scheff et al., 2005). Significant changes in CN expression
and/or activity have also been reported in this and other models
of acute injury (Huang et al., 2005; Liu et al., 2005; Shioda et al.,
2006; Bales et al., 2010; Rosenkranz et al., 2012), although the
nature of the change shows considerable variability from study to
study. All end point measures were taken at 7 d after CCI, at
which time CA3 presynaptic input into CA1 of the ipsilateral
hemisphere has plateaued (and is functionally comparable to the
contralateral hemisphere), but CA1 postsynaptic strength is still
impaired (Norris and Scheff, 2009; Norris et al., 2016).
Figure 1, A and B, shows the appearance of a 45– 48 kDa CN
fragment in the hippocampus, ipsilateral to CCI, at 7 d after
injury (p 	 0.05, n  5). This fragment is similar in size to the
constitutively active CN (aCN) proteolytic fragment expressed in
rat primary hippocampal cultures exposed to excitotoxic insults
(Liu et al., 2005) or oligomeric A peptides (Mohmmad Abdul et
al., 2011) (also see Fig. 1A, 45 kDa aCN lane). Previous work has
shown that aCN can appear at high levels in nervous tissue of
intact rodents as a result of acute injury (Huang et al., 2005; Liu et
al., 2005; Shioda et al., 2006), elevated amyloid levels (Abdul et
al., 2009), or progressive neurodegeneration (Wu et al., 2010;
Mohmmad Abdul et al., 2011), where it may contribute to syn-
aptic deficits, cell death, and neuroinflammation, among other
pathologic processes (Norris, 2014).
To investigate possible changes in the CN-dependent tran-
scription factor NFAT, we used an electrophoretic mobility shift
assay (EMSA) based on a well characterized NFAT-binding oli-
gonucleotide probe derived from the IL4 enhancer region (Neal
and Clipstone, 2001). Using IRDye-labeled probe, we observed a
prominent protein-DNA complex (blue arrowheads, Fig. 1C)
and a more variable and faint complex (black arrowheads, Fig.
1C) in hippocampal tissue fractions from both hemispheres of
injured (n  8) and sham (n  5) rats at 7 d after injury. Both of
these bands were displaced when EMSAs were performed in the
presence of unlabeled wild-type probe, but not with a mutant
probe, confirming that observed bands reflect NFAT-specific
binding. The intensity of the higher-molecular-weight complex
(blue arrowheads) was increased in the ipsilateral relative to the
contralateral hemisphere of injured, but not sham-operated, rats
at 7 d after CCI (p 	 0.05). Supershift/blockshift experiments
were then performed to identify which CN-dependent NFAT
isoform(s) (NFATs 1– 4) gave rise to the DNA-protein com-
plexes. The NFAT1 antibody caused a clear supershift, indicated
by the red asterisk in Figure 1C. The NFAT2 and 3 antibodies did
not perceptibly alter the basic EMSA, indicating that they were
not part of the complex. Finally, the NFAT4 antibody completely
blocked the formation of the DNA–protein complex (see blue
asterisk in Fig. 1C for where the complex normally migrates). For
purposes of quantification, each “pair” of contralateral control
and ipsilateral hippocampal homogenates was assayed on one gel.
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Because the NFAT4 antibody entirely
blocked the formation of the DNA-
protein complex (indicated by the blue ar-
row), this band was quantified and used to
estimate total NFAT4 binding. For
NFAT1, the supershifted band, indicated
by the red asterisks, was quantified for
each sample set. The quantitative data are
shown in Figure 1D. There was a clear and
significant increase in the DNA-binding
activities of NFATs 1 and 4 in the ipsilat-
eral hippocampi of the CCI animals, with
little change observed across hemispheres
in the shams.
Previous work has shown that NFATs
1 and 4 can appear in astrocytes as the
result of injury or disease (Abdul et al.,
2009; Serrano-Pérez et al., 2011; Caraveo
et al., 2014). To determine whether the
expression differences for NFATs 1 and 4
revealed by EMSA analyses (Fig. 1C,D) are
associated with activated astrocytes after
CCI, we colabeled coronal sections from
injured rats (7 d after CCI) with NFAT
and GFAP antibodies and imaged sections
using confocal microscopy. As shown in
Figure 2, we observed a striking increase
in GFAP labeling (shown in red) in the
hippocampus of the ipsilateral hemi-
sphere, consistent with robust injury-
dependent astrocyte activation. Although
both NFAT isoforms exhibited diffuse
labeling in the hippocampus of the con-
tralateral hemisphere, there were clear dif-
ferences in the distribution of the two
isoforms in regard to cell type expression
and injury. NFAT1 showed very little
colocalization with GFAP-positive astro-
cytes in any region of the hippocampus
examined regardless of hemisphere (Fig.
2A). Interhemispheric differences in
NFAT1 labeling were characterized pri-
marily by a shift to a punctate labeling pat-
tern in the ipsilateral hippocampus and
may be associated with proliferating mi-
croglia or infiltrating peripheral cells. In
contrast, NFAT4 showed extensive colo-
calization with GFAP-positive astrocytes,
especially in CA1 (Fig. 2B). In the ipsilat-
eral hippocampus, the labeling intensity
for NFAT4 was generally increased in pro-
portion to the increase in GFAP labeling
intensity. There was little evidence for the
expression of either NFAT isoform in
neuronal cell bodies, particularly in pyra-
midal neurons.
Interestingly, NFAT4/GFAP coloca-
lization showed marked heterogeneity
across different regions of the hippocam-
pus (Fig. 3). NFAT4 colocalization with GFAP was extensive in
the stratum lacunosum/moleculare, stratum radiatum, and stra-
tum oriens of CA1 (Fig. 3A–C), as well as the molecular layers and
hilar regions of the dentate gyrus (Fig. 3M,N), but was much less
apparent in the neuronal cell body layers (Fig. 3, cf. H vs I, N vs
O). Moreover, in contrast to an earlier study that used a kainic
acid insult (Serrano-Pérez et al., 2011), we did not observe exten-
sive colocalization of NFAT4 in astrocytes of CA3 even though
Figure 1. Changes in CN and NFAT signaling properties at 7 d after CCI. A, Representative Western blot for the CN A subunit in rat
hippocampal whole-cell lysates from rat contralateral and ipsilateral hemispheres at 7 d after CCI. Whole-cell lysates from primary astrocyte
cultures infected with adenovirus (Ad) expressing a constitutively active 45 kDa CN fragment (aCN) were run in parallel. Injury was associ-
ated with an increase in the proteolysis of CN to a 45– 48 kDa fragment, similar in size to the fragment found in Ad-aCN-infected astrocyte
cultures. B, Mean
SD level (percentage contralateral hemiphere levels) of proteolysis in hippocampal homogenates in contralateral and
ipsilateral hemispheres. p	0.05, paired t test. C, Representative EMSA for hippocampal homogenates from the ipsilateral and contralat-
eral hemispheres of rats exposed to CCI or to sham surgery. NFAT-binding probe was added to homogenates with and without antibodies
(Ab) to each of the 4 CN-dependent NFAT isoforms to show supershifts and/or block shifts. Unlabeled WT (wt) and mutant (mt) DNA probe
was included in some conditions to demonstrate DNA-binding specificity of the labeled probe. Bands denoted by the blue arrowheads
reflect total NFAT binding. Red asterisks point to bands that were supershifted in response to inclusion of the NFAT1 antibody. Blue asterisks
appear next to lanes where the NFAT4 antibody was included with the DNA-binding probe and illustrate a clear block shift. The black
arrowheads point to bands that were relatively insensitive to antibody treatment conditions and likely reflect nonspecific binding. No gel
shifts or block shifts were seen after inclusion of the NFAT 2 and 3 antibodies, suggesting that these isoforms did not significantly contribute
to total NFAT binding under these conditions. D, Mean
SD DNA-binding activity expressed as percentage of sham contralateral condition
levels. NFAT1 was assessed from the supershifted bands obtained with the NFAT1 antibody (see red asterisks in C). NFAT 4 was assessed
fromthebandsassociatedwithbluearrowheadsin C.n.s.,Nonsignificant ipsilateralversuscontralateral;*p	0.05;p	0.01ipsilateral
versus contralateral, Fisher’s PLSD test.
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numerous activated astrocytes were found in this region
after injury (Fig. 3B, J–L). This discrepancy may be attributable to
differences in the type of cellular degeneration occurring after
kainic acid treatment versus CCI. Regardless, these observations
suggest possible phenotype differences between astrocytes in dif-
ferent hippocampal subregions.
Use of AAV-Gfa2-VIVIT to inhibit astrocytic CN/NFAT
signaling selectively in intact rats
To investigate the impact of astrocytic CN/NFAT signaling on func-
tional outcome after TBI, we used an AAV-mediated gene delivery
approach. Adult rats received bilateral hippocampal injections of
AAV2/5 vectors expressing the NFAT inhibitor VIVIT (coupled to
EGFP) or EGFP alone (control, CT). Some rats received identical
injections of vehicle as an additional control. At approximately 8
weeks after AAV treatment, rats were subjected to a moderate CCI
injury (Fig. 4A). To limit transgene expression to astrocytes, AAV
vectors expressed the human GFAP promoter (Gfa2) (de Leeuw et
al., 2006; Lee et al., 2008). As shown in our earlier work, a single
injection (8 l) of high titer (1012 ifu/ml) AAV-Gfa2 vectors into the
hippocampus results in wide spread infection across all hippocam-
pal subregions (Fig. 4B). Because CN is ubiquitously expressed and
found at particularly high levels in hippocampal neurons, it was
important to verify that AAV-Gfa2-
mediated transgene expression occurred ex-
clusively in astrocytes. Confocal microscopy
was used to inspect the possible colocaliza-
tion of AAV-dependent EGFP expression
with neurons (MAP2b; Fig. 4E,F) and as-
trocytes (GFAP; Fig. 4D,G). As shown in
Figure 4G, EGFP expression in CA1 strongly
colocalized with GFAP (Fig. 4G,H), but
there was no overlap between EGFP and
MAP2b (Fig. 4F,H). Nearly identical obser-
vations were made in other hippocampal
subregions as well (data not shown).
To further confirm that AAV-Gfa2
vectors selectively targeted astrocytes,
we performed immunodepletion exper-
iments (Fig. 4I ). Hippocampi from
AAV-Gfa2-EGFP-infected rats were ex-
tracted and triturated into single-cell
suspensions, which were then placed in
a Microfuge tube and treated with
GLAST antibodies (to tag astrocytes)
coupled to metal Dynabeads. Tubes
were then placed in a magnetic rack to
pull out bead-coupled cells from the
suspension. The fraction bound to the
beads is referred to as AE, whereas the
unbound fraction is referred to as AD.
Some suspensions were passed through
the same protocol, but were not treated
with GLAST antibodies and served as
MD and ME control fractions. Western
blots were then performed to determine
which fraction contained EGFP.
As shown in Figure 4J, the astrocyte-
specific marker GFAP was found in the
MD fraction (as expected) and also in the
AE fraction, but not in the AD fraction.
The prominent appearance of -actin
(which is expressed across all cell types) in
the AD fraction demonstrates that the lack of GFAP expression
was not attributable to a simple loss of total protein. These obser-
vations validate the successful immunodepletion of astrocytes in
this protocol. If transgene expression after AAV-Gfa2 treatment
is selective to astrocytes, then EGFP should show a similar expres-
sion pattern to GFAP, which is exactly what was observed: EGFP
appeared in MD and AE fractions, but not in AD fractions. Es-
sentially the same results were observed in four separate animals.
Combined with the confocal images shown in Figure 4, C–H,
these data demonstrate that AAV-Gfa2 vectors selectively target
astrocytes.
The VIVIT peptide, expressed by AAV-Gfa2 vectors, is de-
rived from a critical endogenous CN-docking site (PxIxIT)
found in the regulatory subregion of NFATs 1– 4 (Aramburu
et al., 1999). Numerous studies have shown that VIVIT inhib-
its the nuclear localization or the transcriptional activity of
NFATs in diverse tissues and cell types (Yu et al., 2007). Pre-
viously, we showed that VIVIT inhibited NFAT activity in
primary astrocytes treated with proinflammatory or cytotoxic
factors (Sama et al., 2008; Abdul et al., 2009). Confocal micro-
graphs in Figure 4K show the cellular localization of NFAT4
(red) in EGFP- or VIVIT-expressing astrocytes of AAV-
infected rats. Note that nuclei are labeled blue (DAPI) and that
Figure 2. Confocal microscopic images showing the expression of NFATs 1 and 4 in the hippocampus at 7 d after CCI. A,
B, NFAT and GFAP labeling shown separately and together (merged) in the CA1 region of the hippocampus in contralateral
and ipsilateral hemispheres at 7 d after CCI. For each NFAT isoform, images were obtained from the same coronal plane of
the same animal and are shown with identical brightness and contrast settings. Both NFATs are expressed throughout
stratum radiatum and stratum oriens in the contralateral and ipsilateral hemispheres. NFAT1 (A) exhibited a more punctate
labeling pattern in the ipsilateral hemisphere, but there was little to no colocalization with GFAP-positive astrocytes
regardless of injury. In contrast, NFAT4 (B) was extensively colocalized to GFAP-positive astrocytes (see numerous yellow/
orange cells in merged images) in both hemispheres and was upregulated as a result of injury.
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the EGFP signal (green) has been re-
moved for clarity. In EGFP-expressing
astrocytes, NFAT4 is mostly present in
the cytosol, but also appears throughout
the nucleus (blue) in many cells (Fig.
4K, arrows). In contrast, NFAT4 expres-
sion in VIVIT-expressing astrocytes is
largely excluded from the nucleus (Fig.
4K, arrowheads), consistent with NFAT
inhibition. The average nuclear-to-
cytosolic ratios for NFAT4 measured
from 32– 42 cells per treatment condi-
tion across three animals per group
(10 –16 cells per rat) are shown in Figure
4L. Therefore, AAV-Gfa2 vectors
not only provide selective targeting
of astrocytes (Fig. 4C–J ), they provide
an effective way to limit the nuclear lo-
calization and activation of NFATs in
these cells.
AAV-Gfa2-VIVIT protects synaptic
function in ipsilateral hippocampus
The rat unilateral CCI model is associated
with extensive loss of synaptic contacts in
the CA1 region of the ipsilateral hip-
pocampus (Scheff et al., 2005). Although
there is a remarkable degree of structural
and functional recovery with time after
injury, deficits in basal synaptic strength
are still evident at 7 d after injury in this
model (Norris and Scheff, 2009), provid-
ing a reasonable time point to investigate
the impact of astrocytic CN/NFAT signal-
ing on synaptic function. One advantage
of the rat CCI model, compared with
mouse models or fluid-percussion injury
models, is that moderate injuries to the
ipsilateral hemisphere in adult rats (as investigated here) cause
very few measurable changes in the contralateral hemisphere. For
instance, previous work on oxidative stress markers after unilat-
eral CCI in rats found no changes in the contralateral hemisphere
of injured rats compared with either hemisphere of sham-
operated rats or even to naive rats (Gilmer et al., 2009). Multiple
presynaptic and postsynaptic protein markers, found at reduced
levels in the ipsilateral hippocampus of rats after CCI, are also
unchanged in the contralateral hemisphere compared with
sham-operated controls (Ansari et al., 2013; Scheff et al., 2013).
Similarly, our previous work using electrophysological measures
of synaptic function taken at 2, 7, and 14 d after CCI showed
comparable levels of basal synaptic strength and plasticity in the
contralateral hemisphere of injured and sham-operated rats
(Norris and Scheff, 2009). These results support the validity of
using the contralateral hemisphere as a within-animal control for
synaptic measures after unilateral CCI in rats.
To determine the extent to which astrocytic CN/NFAT signal-
ing influences synaptic function after CCI, we measured basal
hippocampal synaptic strength in slices from ipsilateral and con-
tralateral hippocampi of AAV-treated rats (n  6 – 8 rats/group)
at 7 d after injury (Fig. 5A–D). Field potentials were recorded in
stratum radiatum of area CA1 in response to electrical stimula-
tion of CA3 Schaffer collaterals. Synaptic strength curves were
generated by plotting EPSP slope values against FV amplitudes
across increasing stimulus intensities. As shown in Table 1, all
synaptic strength curve parameters investigated here were statis-
tically comparable across the contralateral hemisphere of injured,
sham-operated, and naive adult (2-month-old) Sprague Daw-
ley rats.
Hippocampal slices from the ipsilateral hemisphere of
AAV-Gfa2-EGFP control rats showed a downward shift in the
synaptic strength curve relative to the contralateral hemi-
sphere within the same animals (Fig. 5A). Moreover, the
EPSP-FV ratio for the ipsilateral hemisphere was reduced in
AAV-Gfa2-EGFP control rats by 130% relative to the con-
tralateral side ( p 	 0.01), indicative of reduced synaptic
strength (Fig. 5D). In contrast, synaptic strength curves were
qualitatively and quantitatively similar across hemispheres in
rats pretreated with AAV-Gfa2-VIVIT-EGFP (Fig. 5B) and
strongly resembled synaptic strength curves recorded in un-
treated sham rats (Fig. 5C) and naive rats (Table 1). The
EPSP-FV ratio in AAV-Gfa2-VIVIT-EGFP rats showed only a
23% reduction in the ipsilateral hemisphere, which was simi-
lar to the ipsilateral hemisphere of sham rats (4% reduction)
and significantly less ( p 	 0.05) than the reduction found in
AAV-Gfa2-EGFP control rats (Fig. 5D).
We next investigated the extent to which astrocytic CN/
NFAT signaling influences synaptic plasticity after TBI. Al-
though LTP is commonly measured in injury and disease
Figure 3. Heterogenous expression of NFAT4 in hippocampus. A, B, Low-power confocal micrographs of the same
coronal slice (ipsilateral hemisphere) showing GFAP (A) and NFAT4 (B) labeling at 7 d after CCI. C–F, Low- (C) and
high-powered (D–F ) confocal images of NFAT4 and GFAP shown alone (E, F ) or merged (C, D) in area CA1 of the hippocam-
pus of the ipsilateral hemisphere. Micrographs illustrate extensive colocalization of NFAT4 throughout astrocyte somata,
nuclei and major processes. G–O, NFAT4 and GFAP labeling in CA1 (G–I ), CA3 (J–L), and the dentate gyrus (M–O) of the
ipsilateral hemisphere. In CA1 and the DG, NFAT4 is found in most astrocytes. The exception is for those astrocytes found
immediately adjacent to neuronal cell body layers, many of which are apparently devoid of NFAT4 (e.g., see arrowheads in
G–I ). Although numerous GFAP-positive astrocytes were found throughout the CA3 region, relatively few of these cells
exhibited NFAT4 colabeling.
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model systems, our previous work with
the rat CCI model did not reveal LTP
deficits in the ipsilateral hemisphere at
7 d after CCI (Norris and Scheff, 2009).
In contrast, we recently found that the
induction of LTD in CA1 using a 15
min/1 Hz stimulus train is significantly
enhanced in the ipsilateral hemisphere
at both 7 and 14 d after injury (Norris et
al., 2016). To confirm these observa-
tions, we used a similar 1 Hz stimulus
paradigm to induce LTD in the ipsilat-
eral and contralateral hemispheres of
injured rats (7 d after CCI) and sham-
operated rats in the absence of AAV
treatment. As shown in Figure 5E, slices
from sham rats and slices from the con-
tralateral hemisphere of injured rats
showed no significant depression (96%
and 101% of baseline, respectively) after
1 Hz stimulation. In contrast, the same
stimulus paradigm caused a modest
(82% of baseline) but significant ( p 	
0.01) depression in ipsilateral slices from
injured rats, confirming that CCI increases
the susceptibility to LTD in the ipsilateral
hemisphere. Similar to these results,
ipsilateral slices from AAV-Gfa2-EGFP-
treated rats showed significant LTD (83%
of baseline, p 	 0.05) after 1 Hz stimulation
(Fig. 5F). In contrast, LTD was completely
prevented in ipsilateral slices from rats
treated with AAV-Gfa2-VIVIT (103% of
baseline). These results suggest that the as-
trocytic CN/NFAT pathway helps to drive
synapse dysfunction in the ipsilateral hip-
pocampus after CCI injury.
AAV-Gfa2-VIVIT prevents the loss of
synapse-related proteins in
ipsilateral hippocampus
In addition to impaired synaptic function
and altered plasticity, CCI is also associ-
ated with the loss of several key synaptic
proteins in the ipsilateral hippocampus
within the first week after injury, includ-
ing the postsynaptic anchoring protein
PSD-95, the presynaptic vesicle dock-
ing protein synapsin 1, AMPA/kainate-
type glutamate receptor isoforms (e.g.,
GluR1), and NMDA-type glutamate re-
Figure 4. AAV-Gfa2 vectors for targeting astrocytic CN/NFAT signaling. A, AAV-Gfa2 vectors expressing EGFP alone (CT) or EGFP
fused with the NFAT-inhibitory peptide VIVIT were bilaterally injected into the hippocampus of adult rats. At 1–2 months after
injection, rats received a unilateral CCI and biomeasures were taken at 7 d after injury. B, Extensive EGFP expression throughout the
molecular layers of the rat hippocampus at 5 weeks after injection. C–H, Confocal micrographs showing labeling patterns for EGFP
(C, F ), GFAP (D, G), and the neuronal marker MAP2B (E, F ) from an AAV-Gfa2-EGFP-infected rat. Higher-magnification images of
the regions shown in F and G are shown in H. There was extensive colocalization between EGFP and GFAP, but nearly no colocal-
ization between EGFP and MAP2b (F, H ). I, Diagram illustration of the protocol used to immunodeplete astrocytes from intact
hippocampal tissue of AAV-Gfa2-EGFP infected rats. Single-cell suspensions were prepared from hippocampal tissue (Steps 1 and
2) and then added to a Microfuge tube. GLAST antibody was added (Step 3) to tag astrocytes. Metal Dynabeads were then added
(Step 4) and tubes were placed in a magnetic rack. The supernatant containing unbound cells was collected (Step 5) and are
referred to as the AD fraction, whereas the antibody-bound fraction contained in the pellet (Step 6) is referred to as the AE fraction.
J, Representative Western blot showing the expression of GFAP, EGFP, and -actin loading control in AD and AE fractions. MD and
ME fractions (no GLAST antibody added) were run in parallel as controls. EGFP appears in the AE fraction, but not in the AD fraction,
confirming that AAV-Gfa2 targets astrocytes selectively. K, Confocal micrographs showing the cellular localization of NFAT4 (red)
in EGFP-expressing cells in rats infected with AAV-Gfa2-EGFP (CT) or AAV-Gfa2-VIVIT-EGFP. Note that astrocyte nuclei are labeled
4
blue (DAPI). Top panels are 2D confocal images and the bot-
tom panels are 3D-rendered images generated from Z stacks.
Note that, for clarity, the EGFP signal is not shown. Arrows
point to cells where NFAT4 is found distributed across both the
cytosolic and nuclear compartments. Arrowheads point to
cells where NFAT4 is largely excluded from the nucleus. L,
Mean 
 SD for the nuclear-to-cytosolic ratio for NFAT4 in rats
treated with AAV-Gfa2-EGFP or AAV-Gfa2-VIVIT (n  3 rats
per group). VIVIT-treated rats show a significant reduction in
the nuclear localization of NFATs. *p 	 0.01, Student’s t test.
Furman, Sompol et al. • Astrocytic NFAT Signaling and Traumatic Brain Injury J. Neurosci., February 3, 2016 • 36(5):1502–1515 • 1509
ceptor isoforms (e.g., NR2A and NR2B)
(Ansari et al., 2013; Scheff et al., 2013). To
determine whether these changes are sen-
sitive to astrocytic CN/NFAT signaling,
we harvested contralateral and ipsilateral
hippocampus at 7 d after CCI from sham
rats (n  4) and rats treated with AAV-
Gfa2-VIVIT vectors (n  6) and used
Western blot to quantify synaptic pro-
tein levels. For controls, some rats (n 
6) received bilateral injections of AAV-
Gfa2 expressing EGFP alone, whereas
other rats (n  6) received vehicle injec-
tions. Because the two control groups
showed no significant differences on
any of the outcome measures, statistical




the postsynaptic protein PSD-95 and
the GluR1 AMPA receptor subunit were
each significantly reduced, by 56% and
82%, respectively, in the ipsilateral,
relative to the contralateral, hippocam-
pus (Fig. 6 A, D and C,F ). However, the
loss of PSD-95 and GluR1 protein was
comparably small (19% and 27%,
respectively) for rats treated with
AAV-Gfa2-VIVIT. Although levels for
synapsin 1 were not reduced in the
ipsilateral hippocampus of AAV-Gfa2-
EGFP at 7 d after CCI, the AAV-Gfa2-
VIVIT group showed a significant 110%
increase in the ipsilateral hemisphere
( p 	 0.05) (Fig. 6 B, E). Similar to
PSD-95 and GluR1, we also observed a
significant reduction in NR2A (26 

57% mean 
 SD, p 	 0.05) and a small,
nonsignificant reduction in NR2B levels
(20  35% mean 
 SD, p  0.05) in
AAV-Gfa2-EGFP rats (data not shown).
However, these changes were not signif-
icantly altered by AAV-Gfa2-VIVIT
(NR2A 26 
 27% mean 
 SD, p 	
0.05; NR2B 23 
 24% mean 
 SD,
p  0.05). Therefore, together with
measures of basal synaptic strength (Fig.
5A–D), the results show that AAV-Gfa2-
VIVIT protects against the loss of sev-
eral key synaptic proteins after CCI.
Figure 5. Effects of AAV-Gfa2-VIVIT on synaptic strength and plasticity. A, B, CA1 synaptic strength curves constructed from the
mean 
 SEM EPSP slope versus the mean 
 SEM FV amplitude for hippocampal slices from the contralateral and ipsilateral
hemispheres of rats treated with control (CT) AAV-Gfa2-EGFP (A) or with AAV-Gfa2-VIVIT (B). Slices from contralateral and
ipsilateral hemispheres of sham-operated rats (C) are also shown for comparison. Insets in A–C show representative EPSP wave-
forms in each hemisphere matched on the basis of FV amplitude. Note, that for AAV-Gfa2-EGFP CT rats (A), the synaptic strength
curve exhibited a marked downward shift in the ipsilateral relative to the contralateral hemisphere. In contrast, synaptic strength
curves across hemispheres are qualitatively and quantitatively similar in sham rats (C) and rats treated with AAV-Gfa2-VIVIT (B). D,
Mean 
 SD of the EPSP-to-FV ratio in the ipsilateral hemisphere of AAV-treated and sham rats expressed as percentage change
from the contralateral hemisphere. A reduction in the EPSP-to-FV ratio is only observed for AAV-Gfa2-EGFP CT rats.*p 	 0.01
ipsilateral versus contralateral, Fisher’s PLSD test. E, Left, Time plots showing mean 
 SEM EPSP slope values (% baseline) from
slices collected from the contralateral and ipsilateral hemispheres of untreated rats (i.e., no AAV) and the ipsilateral hemisphere of
sham-operated rats. EPSPs were recorded before and for 60 min after delivery of a 15 min train of 1 Hz stimulation (bar).
Representative waveforms in slices from each hemisphere of CCI rats measured before (1) and 60 min after (2) 1 Hz stimulation are
shown in the inset. Calibration bars are 0.5 mV/5 ms. E, Right, Mean 
 SD EPSP slope at 60 min after 1 Hz stimulation in
contralateral and ipsilateral hemispheres and also in the ipsilateral hemisphere of sham-operated rats. Significant LTD was only
observed in slices from the ipsilateral hemisphere of injured rats, *p 	0.05 Fisher’s PLSD test. F, Left, LTD time plots (mean
 SEM
4
EPSP slopes) and bar graphs (right) showing mean 
 SD EPSP
values (% baseline) at 60 min after 1 Hz stimulation in slices
collected from the ipsilateral (injured) hemispheres of AAV-
treated rats. Insets show representative waveforms as de-
scribed for E. Note that LTD is present in the ipsilateral
hemisphere of rats pretreated with AAV-Gfa2-EGFP control
vector (CT), but not in rats treated with AAV-Gfa2-VIVIT. *p 	
0.05, Fisher’s PLSD test.
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AAV-Gfa2-VIVIT does not reduce glial activation after CCI,
but does modulate astrocyte-related proteins involved in
synaptic remodeling
Our work, and work from others, has shown that the CN/NFAT
pathway is an important regulator of the activated phenotypes of
both astrocytes (Norris et al., 2005; Fernandez et al., 2007; Sama
et al., 2008; Serrano-Pérez et al., 2011; Furman et al., 2012) and
microglia (Kataoka et al., 2009; Nagamoto-Combs and Combs,
2010; Shiratori et al., 2010). We previously showed that AAV-
Gfa2-VIVIT protects synaptic function in a chronic, progressive
disease model (APP/PS1 mice) in parallel with reductions in
GFAP and Iba1 (a microglial protein). As shown in Figure 7,
A–D, we performed similar measures on GFAP and Iba1 protein
levels in the rat CCI model. Although we did observe significant
injury-related elevations for both proteins, consistent with ro-
bust glial activation, neither protein marker was sensitive to
AAV-Gfa2-VIVIT treatment. These results suggest that the syn-
aptoprotective effects of AAV-Gfa2-VIVIT after acute injury do
not require a reduction in glial activation.
We next tested whether AAV-Gfa2-VIVIT modulates other
glial-based mechanisms directly involved in synaptic remod-
eling. SPARC and SPARCL1 (hevin) are secreted matricellular
factors that modulate synaptogenesis during development and
possibly after neural injury (Jones et al., 2011; Kucukdereli et
al., 2011; Albrecht et al., 2012; Blakely et al., 2015). Hevin has
been shown to increase the number and size of synapses be-
tween developing neurons in culture, and SPARC appears to
counter these actions (Kucukdereli et al., 2011). Several stud-
ies have reported an increase in SPARC and hevin levels in
activated astrocytes after injury (Jones et al., 2014). Moreover,
a microarray study from our group observed significant
changes in hevin and SPARC gene tran-
scripts in primary neuron/astrocyte cul-
tures as a result of CN overexpression
(Norris et al., 2005).
Western blots of ipsilateral and con-
tralateral hippocampus from rats at 7 d
after CCI revealed differential sensitivities
of SPARC and hevin to injury and AAV
treatment (Fig. 7E–H). Although SPARC
was readily detected in both hemispheres,
it was relatively unaffected by either injury
or AAV treatment (Fig. 7E,F). In con-
trast, hevin showed very low expression in
the contralateral hemisphere, but exhib-
ited increased levels in the ipsilateral hip-
pocampus (p 	 0.05) regardless of virus
treatment, indicative of a putative com-
pensatory reaction to synapse loss with in-
jury (Fig. 7G,H). Remarkably, hevin was
also significantly affected by AAV-Gfa2-
VIVIT treatment. Among the proteins in-
vestigated in this study, hevin was the only
one to show a change in expression in the
contralateral hemisphere across virus
treatment groups, with significantly
greater levels appearing in rats treated
with AAV-Gfa2-VIVIT (p 	 0.05). More-
over, the effects of injury and AAV-Gfa2-
VIVIT were synergistic, such that the
highest levels of hevin were found in the
ipsilateral hemisphere of AAV-Gfa2-
VIVIT-treated rats (p 	 0.001). These re-
sults suggest that AAV-Gfa2-VIVIT may increase and/or
promote synaptic recovery after injury by driving the expression
of the prosynaptogenesis factor hevin.
Discussion
Astrocyte activation and the CN/NFAT pathway after
acute injury
Recent advances in genetic approaches, including the use of cell-
type-specific promoters to selectively target astrocyte signaling path-
ways, have greatly increased our understanding of the functional
impact of activated astrocytes. Several targeted approaches to limit-
ing astrocyte activation have been reported, including the suppres-
sion of astrocyte proliferation (Bush et al., 1999), the deletion of
astrocyte intermediate filament proteins (Pekny et al., 1999; Lund-
kvist et al., 2004), and the knock-down/inhibition of key inflamma-
tory signaling pathways (Okada et al., 2006; Herrmann et al., 2008;
Wanner et al., 2013). These manipulations have revealed many ap-
parently protective functions of activated astrocytes after acute CNS
trauma; for example, the formation of protective glial scars, support
Figure 6. AAV-Gfa2-VIVIT protects against the loss of synaptic proteins. A–C, Representative Western blots and mean 
 SD
levels (D–F) for hippocampal synaptic proteins in the contralateral and ipsilateral hemispheres of rats treated with AAV-Gfa2-EGFP
(CT) or AAV-Gfa2-VIVIT. Protein levels in D–F are from the ipsilateral hemisphere and are expressed as the percentage change from
the contralateral hemisphere. The percentage change in the ipsilateral versus contralateral hemisphere of sham controls are also
provided. Levels for PSD95 and GluR1 showed significant reductions in the ipsilateral hemisphere of AAV-Gfa2-EGFP rats, *p 	
0.05 ipsilateral versus contralateral, Fisher’s PLSD test, but not in the ipsilateral hemisphere of VIVIT-treated rats. Although Syn1
was not significantly reduced with injury, protein levels in the ipsilateral hemisphere were significantly increased by pretreatment
with AAV-Gfa2-VIVIT. *p 	 0.05 ipsilateral versus contralateral, Fisher’s PLSD test, n  5– 6 rats per group.
Table 1. CA3–CA1 synaptic strength curve parameters (mean  SD) for naive rats,
sham-operated rats, and AAV-treated rats 7 d after CCI
Condition EPSP/FV ratio Curve amplitude Curve slope Curve ½ max
Naive 1.71 
 0.72 1.31 
 0.25 0.15 
 0.05 0.35 
 0.11
Sham contra 1.49 
 0.27 1.20 
 0.26 0.11 
 0.03 0.28 
 0.07
Sham ipsi 1.58 
 0.19 1.34 
 0.16 0.13 
 0.03 0.33 
 0.11
EGFP/CT contra 1.87 
 0.30 1.40 
 0.12 0.11 
 0.03 0.29 
 0.07
EGFP/CT ipsi 1.15 
 0.65* 0.78 
 0.22* 0.12 
 0.06 0.30 
 0.12
VIVIT contra 1.66 
 0.23 1.42 
 0.64 0.12 
 0.05 0.32 
 0.14
VIVIT ipsi 1.81 
 0.43 1.41 
 0.70 0.12 
 0.06 0.37 
 0.13
n  6 –10 rats/group.
*p 	 0.05 versus EGFP/CT contra, Fisher’s PLSD.
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of the blood–brain barrier, myelin preservation, and/or the protec-
tion of neuronal viability. In contrast, other reports have suggested
that activated astrocytes have a detrimental impact on nervous tis-
sue. For instance, suppression of astrocyte activation via the com-
bined knock-down of GFAP and vimentin led to improved synaptic
recovery in the outer molecular layer of the dentate gyrus after an
entorhinal cortex lesion (Wilhelmsson et al., 2004). These observa-
tions highlight the complexity and possibly the heterogeneity of as-
trocyte activation during injury and disease.
The present study sought to inhibit astrocyte activation in the rat
CCI model by selectively inhibiting the CN/NFAT pathway in astro-
cytes. In many cell types, CN/NFATs are key transcriptional regula-
tors capable of driving striking changes in cellular phenotype
(Crabtree and Olson, 2002; Horsley and Pavlath, 2002; Hogan et al.,
2003; Wilkins and Molkentin, 2004; Hassoun et al., 2009). Although
less attention has focused on CN/NFAT signaling in the CNS,
mounting evidence suggests that CN/NFATs are associated with
phenotype changes (i.e., activation) in astrocytes (Fernandez et al.,
2007; Sama et al., 2008; Serrano-Pérez et al., 2011; Furman et al.,
2012) and microglia (Kataoka et al., 2009; Nagamoto-Combs and
Combs, 2010; Shiratori et al., 2010). In primary cultures, CN/NFAT
induces numerous immune/inflammatory pathways, many of
which are suppressed by the NFAT inhibitor VIVIT (Sama et al.,
2008; Nagamoto-Combs and Combs, 2010). Previously, we showed
that VIVIT expression in astrocytes over the course of 10–11 months
using AAV-Gfa2 vectors was associated with a reduction in bio-
chemical and morphological markers of glial activation in a mouse
model (APP/PS1) of AD (Furman et al., 2012). Similar to cell culture
studies, the effects of AAV-Gfa2-VIVIT in APP/PS1 mice were ben-
eficial in nature and included improved synaptic function and cog-
nition, suggesting that astrocyte activation can exacerbate neural
dysfunction, at least in the context of progressive amyloid pathology.
Together, these studies provided seemingly strong rationale for
using AAV-Gfa2-VIVIT to test the impact of activated astrocytes on
neural function in an intact animal model of TBI. To our surprise,
however, AAV-Gfa2-VIVIT had little to no effect on GFAP or Iba1
levels in brain-injured rats. If anything, AAV-Gfa2-VIVIT precipi-
tated an increase in Iba1 levels in ipsilateral hippocampus, consistent
with greater microglial activation. This apparent discrepancy with
earlier findings in APP/PS1 mice could indicate fundamental differ-
ences in the activated glial phenotype(s) associated with acute injury
versus progressive neuropathology (i.e., amyloid deposition). In-
deed, there is strong evidence to suggest that multiple phenotypic
characteristics of activated astrocytes, including transcriptional pro-
file and proliferative capacity, can differ significantly depending on
the nature of the insult and/or underlying pathology (Zamanian et
al., 2012; Sirko et al., 2013). It is also possible that the relative contri-
bution of astrocytes and CN/NFAT signaling to glial activation, and
neuroinflammation in general, is greater in chronic disease condi-
tions relative to acute injury. Regardless, the synaptoprotective ef-
fects of AAV-Gfa2-VIVIT, in the face of robust glial activation,
suggests that the astrocytic CN/NFAT pathway influences neural
function through mechanisms that are independent of classic neu-
roinflammatory signaling mediators.
Effects of AAV-Gfa2-VIVIT on synaptic function markers
Although the impact of AAV-Gfa2-VIVIT on glial activation ap-
peared markedly different in the rat CCI model compared with APP/
PS1 mice, the beneficial effects of VIVIT treatment on synaptic
function were highly similar. The large reduction in synaptic
strength measured in ipsilateral slices from AAV-Gfa2-EGFP con-
trol rats was essentially absent in AAV-Gfa2-VIVIT-treated rats.
AAV-Gfa2-VIVIT also prevented the loss (or hastened the recovery)
of several synaptic proteins and reduced susceptibility to LTD in
injured hippocampus. Although the specific mechanisms linking as-
trocytic CN/NFATs to impaired synaptic function remain unsettled,
Western blots suggested a possibly important role for hevin, an
astrocyte-secreted protein that regulates physical interactions be-
tween cells and the extracellular matrix in a variety of tissues (Sulli-
van et al., 2004; Jones and Bouvier, 2014). The dynamic interactions
between hevin and SPARC have been proposed as a critical mecha-
nism for fine tuning synaptic networks during development
Figure 7. AAV-Gfa2-VIVIT does not alter GFAP or Iba1 levels, but causes an increase in hevin
levels. Representative Western blots (A, C) and mean 
 SD. GFAP and Iba1 protein levels (B, D)
in the contralateral and ipsilateral hippocampus of AAV-treated rats at 7 d after CCI. Note that
both glial markers showed a significant increase in the hippocampus of the ipsilateral hemi-
sphere, but were not significantly altered by pretreatment with AAV-Gfa2-VIVIT. #p 	 0.001
ipsilateral versus contralateral, Fisher’s PLSD. n  5– 6 rats, group. E–H, Representative West-
ern blots (E, G) and mean 
 SD SPARC and hevin protein levels (F, H) in the contralateral and
ipsilateral hippocampus of AAV-treated rats at 7 d after CCI. No virus or injury-dependent effects
were observed for SPARC. In contrast, hevin was sensitive to both injury and AAV treatment. In
both AAV groups, hevin was elevated in the ipsilateral relative to the contralateral hemisphere.
Overall hevin levels were greater in the VIVIT-treated group regardless of hemisphere, but were
highest in the injured hemisphere. *p 	 0.05; #p 	 0.001 ipsilateral versus contralateral,
Fisher’s LSD, n  5– 6 rats.
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(Kucukdereli et al., 2011) and possibly after neural injury (Blakely et
al., 2015). Similar to previous reports (Lively and Brown, 2008;
Lively et al., 2011), we observed an injury-related increase in hevin
levels in the rat CCI model. Perhaps more remarkably, hevin expres-
sion was strongly induced by VIVIT, an effect that was potentiated
with injury. It is possible that elevated NFAT activity in activated
astrocytes keeps hevin expression somewhat in check through direct
transcriptional suppression. Conversely, NFATs may limit the activ-
ity/expression of other transcription factors that stimulate hevin
induction.
In addition to hevin, there are many other possible astrocyte-
based mechanisms that could link CN/NFAT signaling to synaptic
function. For instance, complement components such as C3
are associated with astrocyte activation (Tomimoto et al., 1997; Car-
dinaux et al., 2000) and synapse loss (Stevens et al., 2007) and are
sensitive to CN activity (Norris et al., 2005). Astrocytes also protect
neuronal viability and fine tune synaptic transmission by removing
excess glutamate from the extracellular milieu (Sattler and Roth-
stein, 2006), a process that is protected by VIVIT in primary culture
models of neuroinflammation and amyloid toxicity (Sama et al.,
2008; Abdul et al., 2009). Alternatively, astrocytic CN/NFAT signal-
ing may stimulate the release of excitotoxic factors that disrupt
neuronal Ca2 dysregulation, which in turn lead to synapse dys-
function, particularly in regard to the expression of synaptic plastic-
ity. LTD, for example, is normally absent in hippocampal slices from
healthy adult rodents when the bath Ca2/Mg2 concentrations are
at a one-to-one ratio (O’Dell and Kandel, 1994; Norris et al., 1996;
Vouimba et al., 2000; Foster and Kumar, 2007; Shankar et al., 2008;
Dumas, 2012), but is much easier to induce in slices under condi-
tions that promote Ca2 dysregulation such as aging, injury, and
elevated amyloid levels (Norris et al., 1996; Vouimba et al., 2000;
Foster and Kumar, 2007; Shankar et al., 2008; Li et al., 2009; Ma et al.,
2012; Sama et al., 2012; Norris et al., 2016). Clearly, future studies
will be needed to fully characterize NFAT interactions with hevin
and multiple other astrocyte-based signaling mechanisms and their
roles in synaptic recovery and repair.
NFAT isoforms and astrocyte signaling after CCI
Similar to peripheral tissues, changes in glial signaling may hinge
upon the expression of specific NFAT isoforms. NFATs 1, 2, and 4
have each been implicated in the production of proinflammatory
cytokines and chemokines in glial cells (Canellada et al., 2008; Perez-
Ortiz et al., 2008; Nagamoto-Combs and Combs, 2010; Neria et al.,
2013). Previously, we observed elevated levels of NFAT1 activation
in astrocytes in human hippocampus at early stages of cognitive
decline associated with AD (Abdul et al., 2009). Other groups have
observed an increase in the localization of NFAT4 to hippocampal
astrocytes, particularly after acute injury (Serrano-Pérez et al., 2011;
Neria et al., 2013; Yan et al., 2014). Consistent with these reports, the
present study found that NFAT–DNA interactions were increased in
the hippocampus after unilateral CCI and attributable largely to the
activities of NFATs 1 and 4. However, confocal micrographs showed
that the expression of NFAT4 is far more selective for astrocytes.
Unlike our work on human tissue, we found little to no evidence
linking NFAT 1 to activated astrocytes in brain-injured rats. It’s pos-
sible that NFAT1 is primarily associated with microglia and/or infil-
trating immune cells in rodents or that its activity is strongly
stimulated in astrocytes at earlier time points after injury, but then
recedes with time. There may also be significant differences in the
expression and function of different NFAT isoforms across rodents
and humans. Further work using biochemical and fluorescence mi-
croscopy techniques will be needed to evaluate these possibilities and
to identify the cell types that express NFAT1 after injury.
Injury-dependent elevations in activity, coupled with intense
astrocyte-specific expression, suggest that NFAT4 is the most likely
target of VIVIT’s synaptoprotective effects. Interestingly, the colo-
calization of NFAT4 with GFAP exhibited considerable heterogene-
ity across the hippocampus, characterized by extensive labeling in
CA1 and the dentate and little labeling in CA3. Within the CA1 and
dentate regions, NFAT4 was found in the dendritic–axonal layers,
but was largely excluded from the cell body layers. The dendrite/
axonal layers of CA1 and the dentate are where much of the loss (and
subsequent recovery) of synapses take place in the hippocampus
after unilateral CCI (Scheff et al., 2005; Winston et al., 2013), exactly
where NFAT4 upregulation appeared in the present study. These
results suggest that astrocytic NFAT4 is intimately associated with
excitatory synaptic contacts (which are largely excluded from neu-
ronal cell body layers), where it appears to robustly respond to
changes in the functional status and/or viability of these connections.
Although our findings suggest that NFAT4 may negatively affect
synaptic recovery after injury by limiting the expression of hevin (or
other protective factors), the role of NFAT4 in synaptic function
during nondisease/injury conditions is unknown. Previously, we
found few alterations in basal synaptic strength and LTP in wild-type
mice treated for 10 months with AAV-Gfa2-VIVIT, suggesting
that astrocytic NFAT4 does not dramatically alter fundamental
mechanisms of synaptic transmission in adult animals. Nonetheless,
further work will be necessary to clarify the impact of NFAT4 on
synapses under both normal and pathological conditions.
Conclusion
Activated astrocytes have been shown to play both protective and
deleterious roles in acute injury and chronic neurodegenerative dis-
ease. Along with several other earlier reports, the present study sug-
gests that the deleterious actions of activated astrocytes—in
particular the synaptotoxic effects of astrocytes—may hinge upon
the functional status of the CN/NFAT pathway. The results of this
study may offer important clues into how astrocytes affect neuronal
circuit rewiring after acute injury and establish astrocyte-based sig-
naling pathways as possible targets for preserving or improving neu-
ral function after acute head trauma.
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